Plasma YKL-40 in Patients with Metastatic Colorectal Cancer Treated with First Line Oxaliplatin-Based Regimen with or without Cetuximab: RESULTS from the NORDIC VII Study

• Line S. Tarpgaard ,

  * E-mail: line.tarpgaard@rsyd.dk

  Affiliation Department of Oncology, Odense University Hospital, Odense, Denmark and University of Southern Denmark, Odense, Denmark

  ⨯
• Tormod K. Guren,

  Affiliation Department of Oncology, Oslo University Hospital, Oslo, Norway

  ⨯
• Bengt Glimelius,

  Affiliation Departments of Radiology, Oncology and Radiation Science, Uppsala University, Uppsala, Sweden and Department of Oncology and Pathology, Karolinska Institute, Stockholm, Sweden

  ⨯
• Ib J. Christensen,

  Affiliation The Finsen Laboratory, Copenhagen University Hospital, Copenhagen, Denmark and Biotech Research and Innovation Center (BRIC), University of Copenhagen, Copenhagen, Denmark

  ⨯
• Per Pfeiffer,

  Affiliation Department of Oncology, Odense University Hospital, Odense, Denmark and University of Southern Denmark, Odense, Denmark

  ⨯
• Elin H. Kure,

  Affiliation Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

  ⨯
• Halfdan Sorbye,

  Affiliation Department of Oncology, Haukeland University Hospital, Bergen, Norway

  ⨯
• Tone Ikdahl,

  Affiliation Department of Oncology, Oslo University Hospital, Oslo, Norway

  ⨯
• Mette Yilmaz,

  Affiliation Department of Oncology, Aalborg Hospital, Aalborg, Denmark

  ⨯
• Julia S. Johansen,

  Affiliation Departments of Oncology and Medicine, Herlev Hospital, Copenhagen University Hospital, Copenhagen, Denmark

  ⨯
• Kjell Magne Tveit

  Affiliation Department of Oncology, Oslo University Hospital, Oslo, Norway

  ⨯